Salicylic Acid and Risk of Colorectal Cancer: A Two-Sample Mendelian Randomization Study

0552788 - ÚEM 2022 RIV CH eng J - Journal Article
Nounu, A. - Richmond, R.C. - Stewart, I.D. - Surendran, P. - Wareham, N.J. - Butterworth, A. - Weinstein, S.J. - Albanes, D. - Baron, J.A. - Hopper, J.L. - Figueiredo, J.C. - Newcomb, P.A. - Lindor, N.M. - Casey, G. - Platz, E.A. - Marchand, L.L. - Ulrich, C.M. - Li, Ch.I. - van Dujinhoven, F.J.B. - Gsur, A. - Campbell, P.T. - Moreno, V. - Vodička, Pavel - Vodičková, Ludmila - Amitay, E. - Alwers, E. - Chang-Claude, J. - Sakoda, L.C. - Slattery, M.L. - Schoen, R.E. - Gunter, M.J. - Castellví-Bel, S. - Kim, H.R. - Kweon, S.S. - Chan, A.T. - Zheng, W. - Bishop, D.T. - Buchanan, D.D. - Giles, G.G. - Gruber, S.B. - Rennert, G. - Stadler, Z.K. - Harrison, T.A. - Lin, Y. - Keku, T.O. - Woods, M.O. - Schafmayer, C. - Van Guelpen, B. - Gallinger, S. - Hampel, H. - Berndt, S.I. - Pharoah, P.D.P. - Lindblom, A. - Wolk, A. - Wu, A.H. - White, E. - Peters, U. - Drew, D.A. - Scherer, D. - Bermejo, J.L. - Brenner, H. - Hoffmeister, M. - Williams, A.C. - Relton, C.L.
Salicylic Acid and Risk of Colorectal Cancer: A Two-Sample Mendelian Randomization Study.
Nutrients. Roč. 13, č. 11 (2021), č. článku 4164. E-ISSN 2072-6643
Institutional support: RVO:68378041
Keywords : salicylic acid * aspirin * colorectal cancer * Mendelian randomization
OECD category: Genetics and heredity (medical genetics to be 3)
Impact factor: 6.706, year: 2021
Method of publishing: Open access
https://www.mdpi.com/2072-6643/13/11/4164

Salicylic acid (SA) has observationally been shown to decrease colorectal cancer (CRC) risk. Aspirin (acetylsalicylic acid, that rapidly deacetylates to SA) is an effective primary and secondary chemopreventive agent. Through a Mendelian randomization (MR) approach, we aimed to address whether levels of SA affected CRC risk, stratifying by aspirin use. A two-sample MR analysis was performed using GWAS summary statistics of SA (INTERVAL and EPIC-Norfolk, N = 14,149) and CRC (CCFR, CORECT, GECCO and UK Biobank, 55,168 cases and 65,160 controls). The DACHS study (4410 cases and 3441 controls) was used for replication and stratification of aspirin-use. SNPs proxying SA were selected via three methods: (1) functional SNPs that influence the activity of aspirin-metabolising enzymes, (2) pathway SNPs present in enzymes' coding regions and (3) genome-wide significant SNPs. We found no association between functional SNPs and SA levels. The pathway and genome-wide SNPs showed no association between SA and CRC risk (OR: 1.03, 95% CI: 0.84-1.27 and OR: 1.08, 95% CI: 0.86-1.34, respectively). Results remained unchanged upon aspirin use stratification. We found little evidence to suggest that an SD increase in genetically predicted SA protects against CRC risk in the general population and upon stratification by aspirin use.
Permanent Link: http://hdl.handle.net/11104/0327883